ABSTRACT -Opioid receptor (MOR) agonists have been shown to be more potent analgesics in male than female rodents. Regulation of spinal MOR-coupled antinociception by 17␤-estradiol (estrogen, E 2 ) and progesterone (P) is also sexually dimorphic; pregnancy levels of E 2 /P activate MOR-coupled analgesic pathways in male but not female rats. We hypothesized that the sexual dimorphic characteristics of MOR-coupled antinociception reflects sexual dimorphism in the regulation of the release from spinal cord of the endogenous MOR agonist, endomorphin 2 (EM2). Parameters of spinal EM2 release manifesting sexual dimorphism include its 1) magnitude: in vitro basal and K ϩ -evoked release of EM2 from spinal tissue of male rats is approximately 50% greater than that observed from spinal cord of females; 2) modulation by ovarian sex steroids: E 2 /P treatment significantly enhanced K ϩ -evoked EM2 release from spinal tissue of males, but not females; and 3) enhancement by opioid receptor blockade: naloxone enhanced stimulated EM2 release from spinal tissue of both males and females, but it augmented basal release from spinal tissue of only males. Enhancement of EM2 release by naloxone reflects negative coupling of MOR to EM2 release and hence its modulation by negative feedback since only activation of MOR, not -or ␦-opioid receptors, was able to inhibit evoked EM2 release. These data reveal that the EM2-MOR spinal analgesic system is more robust and "higher gain" in male versus female rodents. These findings could provide a mechanistic rubric for understanding the male female dichotomy in prevalence and intensity of chronic pain syndromes.
Multiple observations suggest that spinal -opioid receptor (MOR)-coupled analgesic pathways are sexually dimorphic. Males are more sensitive than are females to the antinociceptive properties of the potent MOR agonist, alfentanil (Cicero et al., 1997) . Opioids with activity at MOR, including levorphanol, dezocine, buprenorphine, butorphanol, nalbuphine, and morphine, are also generally more potent and/or effective in males using mechanical nociceptive stimuli (Barrett et al., 2002) . Notably, sex-dependent differences in morphine antinociception have been reported despite the absence of sex-linked differences in morphine serum levels at the time of its peak MOR-mediated antinociceptive effects (Cicero et al., 1996; Boyer et al., 1998; Krzanowska and Bodnar, 1999; Cook et al., 2000; Peckham et al., 2005; Peckham and Traynor, 2006) . This suggests that such differences most likely result from intrinsic sex-related divergence in the sensitivity of the central nervous system to MOR activation (Cicero et al., 1996) .
Regulation of spinal MOR-coupled antinociception by ovarian sex steroids is also sexually dimorphic. In both rats and humans, gestation is accompanied by an opioid antinociception (Gintzler, 1980; Cogan and Spinnato, 1986 ) that is mediated via spinal opioid systems (Dawson-Basoa and Gintzler, 1998) . In rats, the spinal pathways activated during gestation are also those that are activated by pregnancy levels of ovarian sex steroids (Dawson-Basoa and Gintzler, 1998) . Interestingly, although ovarian sex steroids regulate spinal opioid systems in both male and female rats, the nature of the regulation differs (Dawson-Basoa and Gintzler, 1998; Liu and Gintzler, 2000) . Ovariectomized female rats treated with pregnancy levels of estrogen (17-␤-estradiol, E 2 ) and progesterone (P) manifest an antinociception that is mediated by spinal -opioid receptor (KOR) and ␦-opioid receptor (DOR) (Medina et al., 1993; Dawson-Basoa and Gintzler, 1997; . However, spinal MOR, not DOR, is a major component of the antinociception that results from analogous ovarian steroid treatment of orchidectomized male rats (Liu and Gintzler, 2000) . This suggests that in male, but not in female, rats, pregnancy levels of E 2 /P activate MOR-coupled analgesic pathways.
Many endogenous opioid peptides, e.g., enkephalins, dynorphins, and endomorphins, can interact with and activate MOR. Of these, the endomorphins have the highest affinity and discrimination for MOR. Endomorphin (EM) 1 (Tyr-Pro-Trp-Phe-NH 2 ) and EM2 (Tyr-Pro-Phe-Phe-NH 2 ) have a 4000-and 15,000-fold preference for MOR over DOR and KOR, respectively), as well as very high affinity for MOR (K i Ϸ 360 pM). This is consistent with their putative role as endogenous activators of MOR (Zadina et al., 1997) . EM1 and EM2 also produce potent antinociception following i.c.v. (Zadina et al., 1997; Soignier et al., 2000) or i.t. (Sakurada et al., 2000) administration, the latter being abolished by the selective MOR antagonist ␤-funaltrexamine (Sakurada et al., 2000) . These observations underscore the relevance of endomorphins to endogenous MOR-coupled antinociceptive pathways.
The central nervous system distribution of endomorphins and their opioid receptor-type selectivity profiles have been extensively studied, but elucidation of neural regulators of the release of endomorphins and in particular the sex dependence of this regulation has not been assiduously pursued. Based on the reports noted above of sexual dimorphic MORmediated antinociception, we hypothesized that regulation of the release of EM from spinal tissue would also manifest sexual dimorphism. To test this hypothesis, we quantitatively compared basal and evoked release of EM2 from spinal tissue obtained from untreated and hormone-treated male and female rats and the opioid receptor-coupled regulation thereof. Release of EM from spinal cord was studied since it was this region that mediated the previously reported (Liu and Gintzler, 2000) sex-dependent regulation by ovarian steroids of MOR antinociception. Attention was focused on quantifying the release of EM2 (as opposed to EM1) since it is the predominant endomorphin species in spinal cord (Martin-Schild et al., 1999) . Results demonstrate a significantly enhanced robustness of spinal EM2 release from spinal tissue of male versus female rats and sexually dimorphic regulation by ovarian sex steroids. The relationship of these findings to sex-dependent differences in the modulation of and responsiveness to nociceptive stimuli is discussed.
Materials and Methods
Experimental Animals. Experiments employed male and female Sprague-Dawley rats (Charles River, Kingston, NY; 250 -300 g) that were maintained in an approved controlled environment. Food and water were available ad libitum. Surgeries were performed under sodium pentobarbital anesthesia (40 mg/kg i.p.; Anpro Pharmaceutical, Arcadia, CA). All experimental procedures were reviewed and approved by the Animal Care and Use Committee of the State University of New York Downstate Medical Center.
Ovariectomy and Orchiectomy. Female rats were ovariectomized by parting the posterolateral abdominal muscle layers by blunt dissection to expose a thick fat deposit that contained the ovary. The ovarian bundles were tied off with 4-O silk sutures, excised, and removed from the body cavity (Wayneforth and Flecknell, 1992) . The fascia and skin were separately closed with 5-O silk suture. For orchiectomy, making a single cutaneous incision through the scrotal sac and entering the peritoneal cavity exposed testes. The testicular bundles were ligated with 4-O silk suture, and the testes were removed. The cutaneous incision was closed with 5-O silk suture (Wayneforth and Flecknell, 1992) . Ovarian sex steroid treatment was initiated at the time of ovariectomy and orchiectomy.
Ovarian Sex Steroid Administration. The pregnancy blood concentration profile of E 2 and P were simulated in nonpregnant, ovariectomized rats (hormone simulated pregnancy) and orchiectomized male rats via the s.c. implantation of Silastic tubing filled with either a solution of E 2 in sesame oil or crystalline P (Bridges, 1984) . Day one of steroid hormone administration or its vehicle control was initiated at the time of ovariectomy or orchiectomy. Pregnancy-like levels of E 2 and P were achieved by changing the concentration of E 2 in the tubing (10 mm tubing/100 g b.wt.) and by altering the number of 45-mm P implants on days 5, 15, and 19 (see Bridges, 1984; Bridges and Ronsheim, 1987 for details of implantation procedure and comparison with steroid plasma levels of physiological gestation).
Spinal Tissue Preparation. The spinal vertebral column was sectioned at the intervertebral spaces above vertebrae T 12 and L 1 . The lumbar spinal cord contained within this segment (L 1 -L 5 ; 200 -250 mg) was quickly expelled by injecting ice-cold saline into the caudal end, minced using a McIliwain Tissue Chopper (Mickle Laboratory Engineering Co., Guilford, Surrey, UK; 0.3-mm thickness), placed into a chamber (0.35 ml), and superfused (Brandel Superfusion System, Gaithersburg, MD). The Krebs' solution used for superfusion contained 118 mM NaCl, 4.7 mM KCl, 1.2 mM NaH 2 PO 4 , 25 mM NaHCO 3 , 1.2 mM MgCl 2 , 2.5 mM CaCl 2 , 11.1 mM dextrose, and gelatin (saturated with 4 g/l) and gassed with a 95% O 2 /5% CO 2 gas mixture. Additionally, the Krebs' superfusate used to assess basal and stimulated EM2 release contained the protease inhibitors captopril (10 M), thiorphan (0.3 M), bestatin (10 M), and L-leucyl-L-leucine (2 mM) to protect peptides against the degradation resulting from the actions of the tissue proteases.
Superfusion Paradigm. The magnitude of stimulated EM2 release was determined by quantification of the rate of EM2 release into spinal superfusate that contained high potassium (K ϩ ; 50 mM; the content of sodium was proportionally reduced to maintain osmolarity). High K ϩ -evoked release of EM2 was determined over a 3-min period (1.8 ml). This constituted the first cycle of release. Following stimulation with high K ϩ , a 15-min rest period ensued before redetermining basal and evoked release while in the presence of D-Pen 2 ,D-Pen 5 -enkephalin (DPDPE; ␦-opioid receptor agonist), U50,488H (10, 1000 nM; -opioid receptor agonist), sufentanil (1, 10, 100, 1000 nM; -opioid receptor agonist), naloxone (1 M), or nociceptin/ orphanin FQ (N/OFQ; 10, 100, 1000 nM). Responses to N/OFQ were determined with or without blockade of its receptor, ORL1, via 10 M compound 15, a derivative of the ORL1 receptor antagonist J-113397 that does not contain a hydroxymethyl group on the piperidine ring) (Kawamoto et al., 1999) . The effect of compound 15, alone, on basal and evoked release was separately determined. Determination of EM2 release in the presence of selected pharmacological agents constituted the second release cycle. In all cases, the magnitude of K ϩ -evoked release in the presence of drug (cycle 2) was compared with the magnitude of release observed in its absence (cycle 1). We subtracted release in the absence of K ϩ [basal release (B)] from the total release while in the presence of K ϩ [stimulated release (S)] to calculate the increment in evoked release (S Ϫ B). Drug-induced differences in S were calculated by subtracting the value obtained in cycle 2 from that obtained in cycle 1. A third cycle of release was obtained in which the conditions of cycle 1 were repeated to ensure that changes in basal and/or stimulated release of EM2 were attributable to the presence of drug and not simply to the passage of time. Drug effects were always reversed following washout and re-equilibration (cycle 3).
Basal and stimulated superfusate were collected into prechilled tubes on ice. Superfusate containing basal release and evoked release were desalted and concentrated using reverse phase C-18 car-tridges (Sep-Pak; Waters Corp., Milford, MA). EM2 peptide eluted with 70% acetonitrile/0.1% trifluroacetic acid (TFA) was lyophilized to dryness and stored (4°C). Recovery of EM2 was quantitative (Ͼ95%). K ϩ -evoked release of EM2 could be elicited over three cycles, with a 30-min rest interval between exposures to high K ϩ , without observing a significant diminution in the magnitude of release (Ϯ10%).
Radioimmunoassay. EM2 was quantified in spinal superfusate using a radioimmunoassay (RIA) that employed a rabbit antibody (1:10,000) highly specific for this peptide (generously supplied by James Zadina). A standard curve (0.5-16 pg/assay tube) in which the percentage of inhibition of binding was plotted against the log concentration of unlabeled EM2 in the reaction tube was generated in each assay. Bovine serum albumin (0.1%) was included in the assay buffer to minimize nonspecific adherence to the tube surface. Samples were preincubated with anti-EM2 antibody for 48 h (4°C), after which 10,000 to 12,000 cpm 125 I-EM2 (607 Ci/mmol; Peninsula Laboratories, San Carlos, CA) was added, and the reaction mixture was incubated overnight (4°C). Antibody-bound radioactivity was quantified using scintillation proximity. The reaction mixture was transferred to a 96-well plate that was coated with sheep anti-rabbit antibody and impregnated with scintillant (Flashplate; PerkinElmer Life and Analytical Sciences, Waltham, MA). Formation of a rabbit antibody, 125 I-EM2, and sheep anti-rabbit-complex brings the 125 I-EM2 into proximity with the scintillant-impregnated plate bottom, enabling quantification of the antibody-bound tracer. In contrast, nonantibody-bound radioactivity is not brought into sufficient proximity with the scintillant to be detected; thus, it does not confound quantification of antibody-bound radioactivity. Plates were counted by Microbeta Jet Counter (PerkinElmer Life and Analytical Sciences) after incubation for an additional 12 h at 4°C. Values of experimental samples were calculated from the standard curve using the "forecast function" of Microsoft Excel. The minimum detectable concentration ranged from 0.6 to 1.5 pg/assay well, which produced ϳ20% inhibition of maximum binding. A 50% reduction in binding was produced by 11 to 12 pg/assay well. Peptide concentrations were derived from RIA analyses of superfusate that produced between 20 and 75% inhibition of binding, the linear and sensitive portion of the standard curve. All standard and experimental samples were run in triplicate and duplicate, respectively.
The chemical identity of EM2-like immunoreactivity was analyzed by combining high-pressure liquid chromatography (HPLC) fractionation with RIA detection. Spinal superfusate (from two lumbar spinal preparations) were collected under basal and stimulated conditions. The EM2 peptide contained therein was desalted and concentrated using reverse phase C-18 Sep-Pak cartridges as described above. The 70% acetonitrile-0.1% TFA eluate was lyophilized to dryness, resuspended in 40 l of 1% acetonitrile-0.1% TFA, and centrifuged (500g for 5 min). Fractionation by HPLC was accomplished by applying supernatant (20 l) or the same volume of standard peptide onto a 15-cm C-18 column (5 m; Grace Vydac, Province, CA). The column was eluted at a flow rate of 1 ml/min, with a mobile phase containing 0.08% TFA throughout and a linear gradient of acetonitrile ranging from 4% at the start to 70% at 28.6 min. These chromatographic conditions permit authentic EM2 to be separated from other opioid peptides (methionine-and leucine-enkephalin, ␣-endorphin, ␤-endorphin, ␥-endorphin, N-acetylated ␤-endorphin, dynorphin 1-17). HPLC eluates (1-ml fractions) were lyophilized to dryness, and the content of EM2 was determined by RIA as described above. Approximately 89% of the EM2-like immunoreactivity that was contained in spinal tissue superfusate had a retention time comparable with that of standard EM2. The data shown have not been corrected for recovery.
Statistical Analyses. Factorial ANOVAs (general linear model) were used to assess the effect of sex, release condition (basal, K ϩ -evoked), hormone treatment, and drugs on EM2 release. In addition, post hoc tests (least significant difference test) were used to further examine significant effects of the ANOVAs. Log-transformed data were used for all analyses to minimize the effect of any skew in the data set.
Drugs. 
Results
To assess the interaction among sex, release condition (basal, K ϩ -evoked), and hormone treatment, we performed a three-way ANOVA where the first factor of the ANOVA was release condition (basal K ϩ -evoked), the second factor was hormone treatment (untreated, E 2 /P-treated), and the third factor was sex. Significant main effects and interactions were found for all factors. Most notably, a significant three-way interaction was found among sex, hormone, and release conditions (F 1,129 ϭ 15.9, p Ͻ 0.001). The post hoc component of this analysis revealed that the rates of basal and K ϩ -evoked EM2 release from spinal tissue of male rats was significantly greater than from females (basal, 4.58 ϩ 0.06 min versus 2.98 ϩ 0.05 pg/6 min, respectively; K ϩ -evoked, 8.64 Ϯ 0.17 versus 5.76 Ϯ 0.11 pg/6 min, respectively; p Ͻ 0.001 for both comparisons) (Fig. 1, compare A with B) . In addition, the rate of K ϩ -evoked release, but not basal release, of EM2 from the spinal cord of hormone-treated male rats was significantly greater (p Ͻ 0.001) than that from control male rats (K ϩ -evoked, 8.64 Ϯ 0.17 versus 10.53 Ϯ 0.27 pg/6 min; Fig. 1A) . However, in spinal tissue obtained from female rats, hormone condition affected neither basal nor evoked EM2 release (p Ͼ 0.3 for both comparisons; Fig. 1B) .
Sex Dependence of Opioid Receptor-Coupled Regulation of EM2 Release. We performed a three-way ANOVA to examine the effects of naloxone (absence or presence) on the rate of EM2 release (basal, K ϩ -evoked) within the context of sex. The three-way interaction was not significant (p ϭ 0.87). However, main effects and all two-way interactions were significant (p Ͻ 0.02). Since the two-way interaction between naloxone and release condition was significant and the three-way interaction, which is the same analysis with the additional factor of sex, was not, the interaction between naloxone and release condition is not sex-dependent. This was examined in greater detail using post hoc tests (least significant difference test). Post hoc comparisons indicated that naloxone had no effect on basal release from spinal cord of females (p ϭ 0.115). In contrast, naloxone significantly enhanced the rate of basal release (ϳ0.95 pg/6 min) from spinal cord of males (p Ͻ 0.001) (Fig. 2A) . Unexpectedly, the stimulated increment in the rate of EM2 release from spinal tissue of females was significantly enhanced by naloxone, as was also observed in spinal tissue of males (p Ͻ 0.001 for both) (Fig. 2B) . It should be noted that in spinal tissue obtained from males, the enhancement of the stimulated increment in the rate of EM2 release produced by naloxone was greater than its effect on basal release (3.7 versus 0.95 pg/6 min; Fig. 2A) . Thus, the ability of naloxone to enhance EM2 release is dependent on release condition in males as well as females.
We further investigated whether or not the magnitude of effect of naloxone on stimulated EM2 release from spinal tissue of males was influenced by hormone treatment. Once again, significant main effects of naloxone (F 1,6 ϭ 754, p Ͻ jpet.aspetjournals.org Downloaded from 0.001) and hormone treatment (F 1,6 ϭ 1262, p Ͻ 0.001) were observed. Most importantly, the interaction between hormone treatment and naloxone was significant (F 1,6 ϭ 16.8, p ϭ 0.006). In other words, the ability of naloxone to enhance stimulated release of EM2 is influenced by the E 2 /P state of male rats (4.6 versus 8.2 pg/6 min) (Fig. 2C) . In contrast, analogous assessment of the influence of E 2 /P on naloxone enhancement of stimulated EM release from spinal cord of female rats indicated a significant main effect only for naloxone (F 1,7 ϭ 63.3, p Ͻ 0.001). There was no significant interaction between naloxone and hormone treatment.
Modulation of K ؉ -Evoked EM2 Release by Opioid Receptor-Type-Selective Agonists. A three-way ANOVA was used to examine the effect of the MOR-selective agonist sufentanil on stimulated EM2 release from spinal tissue obtained from male and female rats. Factors were sex, drug, and dosage. Significant main effects were found for sex (F 1,20 ϭ 71.0, p Ͻ 0.001), drug (F 1,20 ϭ 52.9; p Ͻ 0.001), and dosage (F 3,20 ϭ 5.3; p Ͻ 0.007). No significant drug ϫ sex interactions were found (F 1,20 ϭ 1.8; p ϭ 0.19). To formally analyze dose responsiveness of the inhibition by sufentanil of K ϩ -evoked EM2 release, we used general linear model to perform regression and estimation of slopes for data obtained from spinal tissues of male and female rats. There was a linear dose response function, the slopes of which did not differ between spinal tissue of male and female animals (Fig. 3) .
To assess the effect of DOR-and KOR-selective selective agonists on stimulated EM2 release, the ability of DPDPE and U50,488H, respectively, to inhibit EM2 release was investigated. For DPDPE, a two-way ANOVA failed to reveal any significant main effects or interaction effects for drug and dosage in spinal tissue of male and female rats. Similar results were found for U50,488H (data not shown).
N/OFQ Enhances K ؉ -Evoked EM2 Release. A threeway ANOVA revealed significant main effects for N/OFQ (F 1,15 ϭ 104; p Ͻ 0.001), and sex (F 1,15 ϭ 60.8; p Ͻ 0.001) but none for dosage and none for the interaction between drug and sex. The enhancement of EM2 release by N/OFQ was not dose-dependent and did not differ between spinal tissue of male and female rats (Fig. 4) . A two-way ANOVA was subsequently performed to assess the effect of N/OFQ on basal and evoked EM2 release. Significant main effects were found for release condition (basal, K ϩ -evoked) (F 1,80 ϭ 99.4; p Ͻ 0.001) and drug (presence or absence) (F 1,80 ϭ 6.65; p ϭ 0.012), but no interaction between drug and release condition was detected. However, post hoc analyses revealed that basal release was not influenced by the presence of N/OFQ, but N/OFQ did augment K ϩ -evoked EM2 release (Ϸ30%; p Ͻ 0.005).
Importantly, in the presence of compound 15, an ORL1 receptor antagonist, the enhancing effect of N/OFQ on K ϩ -evoked EM2 release was no longer observable. A two-way ANOVA with N/OFQ (presence, absence) and compound 15 (presence, absence) was performed for the stimulated condition. The main effect for N/OFQ and compound 15 was not significant. However, a significant interaction effect between N/OFQ and compound 15 was observed (F 1,15 ϭ 7.19; p ϭ 0.017), indicating that this ORL1 receptor antagonist modulated (abolished) the effect of N/OFQ (data not shown). An analogous ANOVA was performed to assess the effect of compound 15 on the release condition. The interaction between these two factors was not significant (F 1,20 ϭ 0.56; p ϭ 0.46). Moreover, post hoc tests demonstrated no effect of compound 15 on either basal or evoked EM2 release.
Discussion
The present results demonstrate for the first time sexually dimorphic functionality of the spinal EM2/MOR opioid analgesic pathway. Parameters of spinal EM2 release manifesting sexual dimorphism include its: 1) magnitude, 2) modulation by E 2 /P, and 3) enhancement by opioid receptor blockade. In the aggregate, these data indicate the presence in males of a more robust and dynamic endogenous MORcoupled spinal antinociceptive system. This parallels the earlier reports of increased magnitudes of analgesia in male versus female rodents that results from the exogenous activation of MOR.
The magnitude of in vitro basal and K ϩ -evoked release of EM2 from spinal tissue of male rats is approximately 50% greater than that observed from spinal cord of females. This would add to or synergize with enhanced analgesic consequences of MOR-coupled signaling in males versus females that is reflected by the well established greater antinociceptive potency of MOR agonists in male versus female rodents Fig. 1 . The influence of sex on the magnitude of basal and evoked release of EM2 and its modulation by E 2 /P. Lumbar spinal tissue was obtained from untreated and E 2 /P-treated male (n ϭ 32 and 9, respectively; A) and female (n ϭ 55 and 32, respectively; B) animals and processed as described under Materials and Methods. Eluates (collected over two 6-min periods, 3.6 ml each, for basal release and a 3-min period, 1.8 ml, for stimulated release) were desalted, lyophilized, and assayed by RIA for EM2 immunoreactivity. Each bar represents the mean Ϯ S.E.M. (picograms per 6 min). Basal and evoked EM2 release were 50% higher in spinal tissue obtained from male versus female rats. Enhancing effect of E 2 /P treatment on evoked EM2 release was only observed in males. ‫,ء‬ p Ͻ 0.001 for basal and K ϩ -evoked EM2 release from spinal cord of male versus female rats; ԫ, p Ͻ 0.001 for K ϩ -evoked EM2 release from spinal cord of control male versus hormone-treated male rats. HSP, hormonesimulated pregnancy. jpet.aspetjournals.org Downloaded from (Cicero et al., 1996 (Cicero et al., , 1997 Boyer et al., 1998; Krzanowska and Bodnar, 1999; Cook et al., 2000; Barrett et al., 2002; Peckham et al., 2005; Peckham and Traynor, 2006) . It remains to be established whether or not inferences from data derived from rat spinal tissue generalizes to men and women. This notwithstanding, it is tempting to speculate that sex-dependent differential activity of the spinal EM2/MOR-coupled opioid systems could be a contributory component of the greater prevalence and intensity of chronic pain syndromes in women versus men. Clearly, additional studies will be required to validate this hypothesis, but the current observations could provide a mechanistic framework for beginning to understand the sex-based dichotomy in the chronicity of painful experience in humans.
Sexual dimorphism in the frequency and severity of chronic pain has been very well documented in women. Women are more likely than men to experience recurrent pain, more severe levels of pain, and pain of longer duration (Unruh, 1996) . Such conclusions are supported using ther- Fig. 2 . Opioid receptor blockade enhances spinal release of EM2. Lumbar spinal tissue, obtained from male and female animals, was processed, superfusate collected, and its content of EM2 was determined by RIA as described under Materials and Methods. Basal (A) and K ϩ -evoked (B) EM2 was obtained in the absence or presence of naloxone (1 M). Each bar represents the mean Ϯ S.E.M. (picograms per 6 min). C, hormone treatment increases the naloxone-induced increment in K ϩ -evoked release from spinal cord of males but not females. A and B, ‫,ء‬ p Ͻ 0.001 for the effect of naloxone on basal EM2 release from spinal tissue of males and on K ϩ -evoked release from spinal tissue of males and females. C, ‫,ء‬ p Ͻ 0.001 for the comparison of the effect of naloxone on the increment in K ϩ -evoked rate of release of EM2 from spinal tissue of control male versus hormone-treated males. The magnitude of enhancement of EM2 release produced by naloxone depends on the release condition: naloxone enhancement of stimulated EM2 release from spinal tissue of steroid-treated males (8.2 pg/6 min) Ͼ effect on stimulated release from control males (4.6 pg/6 min) Ͼ effect on basal release (0.95 pg/6 min). NX, naloxone; HSP, hormone-simulated pregnancy; (S Ϫ B), difference between K ϩ -evoked and basal rates of release (n ϭ 3-4).
Fig. 3. Effect of MOR activation on K
ϩ -evoked EM2 release. Lumbar spinal tissue was processed, superfusate was collected, and its content of EM2 was determined by RIA as described under Materials and Methods. Basal and K ϩ -evoked release of EM2 from spinal tissues of untreated male and female rats in the absence or presence of the indicated concentration of sufentanil. Each point represents the mean Ϯ S.E.M. increment in the rate of EM2 release (picograms per 6 min). Sufentanil produced a dose-dependent inhibition of K ϩ -evoked release of EM2 that did not differ among spinal tissue obtained from male and female rats. S Ϫ B, difference between K ϩ -evoked and basal rates of release. n ϭ 3 to 4. Fig. 4 . N/OFQ enhances K ϩ -evoked release of EM2. Lumbar spinal tissue was processed, superfusate was collected, and its content of EM2 was determined by RIA as described under Materials and Methods. Basal and K ϩ -evoked release of EM2 was quantified from spinal tissue of untreated male and female rats in the absence or presence of the indicated concentration of N/OFQ. Each point represents the mean Ϯ S.E.M. increment in EM2 release (picograms per 6 min). As shown in Fig. 1, K ϩ -evoked release of EM2 from spinal cord of males was greater than from spinal cord of females, but both were similarly affected by N/OFQ. S Ϫ B, difference between K ϩ -evoked and basal rates of release. n ϭ 3 to 4.
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jpet.aspetjournals.org mal (Fillingim et al., 1998) , electrical (Walker and Carmody, 1998) , and pressure (Ellermeier and Westphal, 1995) nociceptive stimuli. There is also evidence of sexually dimorphic pain and analgesic mechanisms in laboratory animals (Mogil et al., 1993; Kayser et al., 1996; Liu and Gintzler, 2000; LaCroix-Fralish et al., 2005; Mogil and Chanda, 2005) . Current findings underscore the relevance of sexual dimorphic spinal release of EM2 to understanding sex-based pain and analgesic mechanisms on mechanistic levels. The second notable outcome of this study is the paradoxical finding that the pregnancy blood profile of E 2 /P significantly enhanced K ϩ -evoked EM2 release from spinal tissue of males, but not females. These results are consistent with and provide a neurochemical basis for the earlier demonstration by this laboratory (Dawson-Basoa and Gintzler, 1996; Liu and Gintzler, 2000) that although simulation of the pregnancy blood concentrations of E 2 /P elicits an analogous spinal opioid antinociception in ovariectomized female and orchidectomized male rats, the mechanistic underpinnings of the antinociception are dependent on sex (Dawson-Basoa and Gintzler, 1998; Liu and Gintzler, 2000) . The opioid antinociception elicited by pregnancy blood levels of E 2 /P in ovariectomized female rats is mediated by spinal KOR and DOR; contributions of MOR cannot be detected (Dawson-Basoa and Gintzler, 1996) . In contrast, MOR (together with KOR) mediates the antinociception manifest in orchidectomized males following analogous steroid treatment (Liu and Gintzler, 2000) . The current demonstration of the ability of E 2 /P to augment in vitro-evoked release of spinal EM2 in males but not females is, most likely, a major determinant of the previously reported (Liu and Gintzler, 2000) sex-based differential activation by ovarian sex steroids of spinal MOR-coupled antinociception.
There is precedent for the ability of E 2 and/or P to produce physiological effects in males. For example, P has been shown to enhance testicular secretion (Kalra and Kalra, 1980) . In addition, E 2 treatment has been shown to decrease levels of several neurotransmitters in brain tissue consisting of medulla, pons, midbrain, thalamus, and hypothalamus (Das and Chaudhuri, 1995) . More recently, acute treatment with E 2 was shown to increase the concentration of mRNA encoding the serotonin 2A receptor in the dorsal raphe nucleus as well as the density of serotonin 2A receptor binding sites in numerous brain areas (Sumner and Fink, 1998) . Moreover, consonant with current observations that E 2 /P produces similar antinociception in males and females, sequential treatment with E 2 /P followed by withdrawal of P has been shown to elevate mRNA encoding oxytocin in the paraventricular nucleus of ovariectomized female as well as orchidectomized male rats (Thomas and Amico, 1996) .
The ability of opioid receptor blockade to enhance basal and stimulated release of EM2 indicates its negative modulation by an endogenous opioid(s). Notably, basal release from only spinal tissue of males was enhanced by naloxone. It is unlikely that this sex difference reflects sex-based anatomical differences in localization of MOR on EM2 perikarya and/or terminals since naloxone was able to enhance K ϩ -evoked release of EM2 from the spinal cord of female as well as male rats. It is more probable that the magnitude of facilitation of EM2 release by naloxone is related to the magnitude of opioid receptor activation and thus the magnitude of the release of some endogenous opioid. The ability of MOR activation (but not activation of DOR or KOR) to inhibit release of EM2 implies that EM2 release is subject to feedback inhibition, which is relieved by naloxone.
In this formulation, the magnitude of enhancement of EM2 release by naloxone would be proportional to the magnitude of the release of EM2 itself. This is supported by the observation that the magnitude of facilitation by naloxone of K ϩ -evoked release of EM2 from spinal tissue of E 2 /P-treated males is larger than from spinal tissue of untreated males, which in turn is larger than the enhancement of basal EM2 release. Thus, it is likely that sex-dependent differential regulation of basal EM2 release by naloxone results from the greater magnitude of that release from spinal cord of males versus females (4.58 versus 2.98 pg/6 min, respectively); basal spinal release of EM2 in females may not be sufficient to achieve threshold concentrations required for presynaptic inhibition of EM2 release.
Inhibition of EM2 release by negative feedback inhibition and the MOR agonist sufentanil is consistent with the colocalization of EM2 and MOR in fibers in superficial laminae of the lumbar dorsal horn (Abbadie et al., 2002) . Interestingly, release from spinal tissue of females and males was equally sensitive to sufentanil inhibition, which did not exceed 50%. It is not clear whether or not this inhibitory ceiling results from the presence of an EM2 pool that is resistant to MORcoupled inhibition or if it is a consequence of a restricted distribution of MOR on EM2 neurons. In contrast to MOR, activation of either spinal KOR (via U50,488H) or DOR (via DPDPE) did not produce detectable alteration of EM2 release, indicating the unique importance of MOR to the regulation of EM2 release.
We previously demonstrated the ability of exogenous and endogenous N/OFQ to act as a negative modulator of the evoked release of both spinal dynorphin and methionineenkephalin (Gupta and Gintzler, 2003; Gupta et al., 2001 ). Thus, we were surprised to observe that exogenous N/OFQ facilitated evoked EM2 release from spinal tissue of both male and female rats. The stimulatory effect of N/OFQ on EM2 release from spinal cord could contribute to antinociceptive effects of i.t. N/OFQ in rats reported earlier (Jhamandas et al., 1998) and could also suggest a mechanism for the reciprocal regulation of the release of endogenous spinal opioids. Divergent regulation of spinal opioid release via the same agent is not unprecedented. For example, the negative modulation of spinal dynorphin release by N/OFQ is neutralized following E 2 /P treatment (Gupta et al., 2001) , whereas the ability of N/OFQ to inhibit methionine-enkephalin release persists following identical treatment (Gupta and Gintzler, 2003) . The independent and divergent regulation of the release of spinal opioid peptides would maximize the ability to fine tune the relative contribution of each to antinociceptive processes.
In contrast to the dose-dependent modulation of spinal dynorphin and methionine-enkephalin release by N/OFQ (Gupta et al., 2001; Gupta and Gintzler, 2003) , its modulation of EM2 release appeared to be an all or none step function. It is possible that modulation of EM2 release by N/OFQ that is dose-dependent could be obscured by its steepness and narrow range. Alternatively, the inability to demonstrate dose dependence of its modulation of EM2 release could result from its complex physiology, e.g., N/OFQ inhibits two distinct groups of neurons in the brain stem to cause either hyperalgesia, via the removal of -opioid analgesia, or analgesia (Pan and Hirakawa, 2000) . Complex actions of N/OFQ can also include modulation of multiple parameters of the same system. N/OFQ (i.t.) can enhance the release of spinal substance P and thereby promote nociception, but at higher i.t. concentrations, it can also act postsynaptically to inhibit the actions of substance P (Inoue et al., 1999) . The current experimental paradigm does not have sufficient resolving power to resolve opposing actions of N/OFQ on EM2 release mediated by discrete spinal anatomical sites.
In summary, spinal EM2 release exhibits sexual dimorphism in its magnitude and regulation by ovarian sex steroids. Notably, release from spinal tissue of males is much more robust than is the release from spinal cord of females. The ability of MOR blockade to enhance basal release from spinal tissue of males but not females indicates that in males, spinal EM2 release is also more dynamic and "higher gain," i.e., spinal EM2 release in males can be enhanced by either stimulation or disinhibition or combinations of both. These findings could provide a mechanistic framework for beginning to understand the male female dichotomy in prevalence and intensity of chronic pain syndromes.
